Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Share buy-back week 11/2017


Posted on: 20 Mar 17

Announcement             

20 March 2017 

Coloplast – transactions in connection with share buy-back programme

As mentioned in Announcement No. 2/2017 Coloplast has initiated the second part of the share buy-back programme totalling up to DKK 1bn. This part of the programme of DKK500m is expected to take place from 27 February, 2017 to 28 August, 2017.

The buy-back programme will be structured in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Regulation 2016/1052, also referred to as the "Safe Harbour" rules, which ensure that the company is protected against violation of insider legislation in connection with the buyback programme.

The following transactions have been executed during the period 13 – 17 March 2017:

Date Number of shares Buying price Amount DKK
13 March 2017 10,388 507.02 5,266,900.91
14 March 2017 13,500 506.22 6,834,018.60
15 March 2017 15,500 504.24 7,815,712.25
16 March 2017 11,324 506.05 5,730,481.89
17 March 2017 6,490 508.36 3,299,227.84
Accumulated until now under the programme 196,707 500.03 98,359,073.88

Henceforth, Coloplast owns 3,878,722 treasury B shares of DKK 1 equal to 1.80% of the company’s total share capital.

An overview showing the transaction data for the period 13 - 17 March 2017 is enclosed.

Kind regards,

Investor Relations

Coloplast A/S

Tel. +45 4911 1800

   

For further information, please contact

Investors and analysts                                           

Ellen Bjurgert

Director, Investor Relations

Tel. +45 4911 1800/+45 4911 3376

Email: dkebj@coloplast.com

 

Rasmus Sørensen

Sr. Manager, Investor Relations

Tel. +45 4911 1800/ +45 4911 1786

Email: dkraso@coloplast.com

                                                                                       

Press and the media                                               

Maria Lindeberg

Sr. Media Relations Manager

Tel. 4911 3095

Email: dkmalg@coloplast.com

 

This announcement is available in a Danish and an English language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes ostomy care, urology and continence care and wound and skin care. We operate globally and employ more than 11,000 people.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2017-03 All rights reserved Coloplast A/S, 3050 Humlebæk, Denmark. 

GlobeNewswire
globenewswire.com

Last updated on: 21/03/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.